Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis

Bibliography

• PHILLIPS WG, BREATHNACH SM: Psoriasis: immune in-dicators and treatment. Clin. Immunother. (1994) 1:157–167.
   Google Scholar
• GREAVES MW, WEINSTEIN GD: Treatment of psoriasis. New Engl. J. Med. (1995) 332:581–588.
   PubMed Web of Science ®Google Scholar
• GHADIALLY R, HALKIER-SORENSEN L, ELIAS PM: Effects of petrolatum on stratum corneum structure and func-tion. J. Am. Acad. Dermatol (1992) 26:387–396.
   PubMed Web of Science ®Google Scholar
• LIEM WH, MCCULLOUGH JL, WEINSTEIN GD: Effective-ness of topical therapy for psoriasis: results of a na-tional survey. Cutts (1995) 55:306–310.
   PubMed Web of Science ®Google Scholar
• JAMES VH, MUNRO DD, FEIWEL M: Pituitary-adrenal function after occlusive topical therapy with be-tamethasone-17-vale rate. Lancet (1967) 2:1059–1061.
   PubMed Web of Science ®Google Scholar
• DU VIVIER A: Tachyphylaxis to topically applied ster-oids. Arch. Dermatol (1976) 112:1245–1248.
   PubMed Web of Science ®Google Scholar
• PERRY HO, SODERSTROM CW, SCHULZE RW: The Goeck-erman treatment of psoriasis. Arch. Dermatol (1968) 98:178–182.
   PubMed Web of Science ®Google Scholar
• STERN RS, ARMSTRONG RB, ANDERSON TF et al: Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomised study. J. Am. Acad. Dermatol (1986) 15:546–552.
   PubMed Web of Science ®Google Scholar
• REICHERT U, JACQUES Y, GRANGERET M et al: Anti-res-piratory and antiproliferative activity of anthralin in cultured human keratinocytes. J. Invest. Dermatol (1985) 84:130–134.
   PubMed Web of Science ®Google Scholar
• HEGEMANN L, FUCHTMANN R VAN ROOJIEN LAA et al:The anti-psoriatic drug, anthralin, inhibits protein ki-nase C - implications for its mechanism of action. Arch. Dermatol Res. (1992) 284:179–183.
   PubMed Web of Science ®Google Scholar
• BINDERUP L, BRAMM E: Effects of a novel vitamin D analogue MC903 on cell proliferation and differentia-tion in vitro and on calcium metabolism in vivo. Bio-chem. Pharmacol (1988) 37:889–895.
   PubMed Web of Science ®Google Scholar
• MULLER K, SVENSON M, BENDTZEN K: 1 Alpha,25-dihy-droxyvitamin D3 and a novel vitamin D analogue MC903 are potent inhibitors of human interleukin 1 in vitro. Immunol. Lett. (1988) 17:361–366.
   PubMed Web of Science ®Google Scholar
• MURDOCH D, CLISSOLD SP: Calcipotriol: a review of its pharmacological properties and therapeutic use in pso-riasis vulgaris. Drugs (1992) 43:415–429.
   PubMed Web of Science ®Google Scholar
• DWYER C, CHAPMAN RS: Calcipotriol and hypercalcae-mia. Lancet (1991) 338:764–765.
   PubMed Web of Science ®Google Scholar
• BAKER H: The influence of chloroquine and related drugs on psoriasis and keratoderma blenorrhagicum. Br. J. Dermatol. (1966) 78:161–166.
   Web of Science ®Google Scholar
• GUPTA AK, ELLIS CN, SIEGEL MT et al.: Sulfasalazine improves psoriasis. A double-blind analysis. Arch. Der-matol. (1990) 126:487–493.
   Google Scholar
• STERN RS, LAIRD N, MELSKI J et al.: Cutaneous squamous-cell carcinoma in patients treated with PUVA. New Engl. J. Med. (1984) 310:1156–1161.
   PubMed Web of Science ®Google Scholar
• STERN RS, ABEL E, WEINTRAUB B et al.: Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radia-tion. New Engl. J. Med. (1990) 322:1093–1097.
   PubMed Web of Science ®Google Scholar
• CHIEN D-S, SANDRI RB, TANG-LIU DDS: Systemic phar-macokinetics of acitretin, etretinate, isotretinoin, and acetylenic retinoids in guinea pigs and obese rats. Drug Metab. Disp. (1992) 20:211–217.
   PubMed Web of Science ®Google Scholar
• MANSBRIDGE JN, KNAPP AM: Changes in keratinocyte maturation during wound healing. J. Invest. Dermatol (1987) 89:253–263.
   PubMed Web of Science ®Google Scholar
• KRUEGER GG: A perspective of psoriasis as an aberra-tion in skin modified to expression by the inflamma-tory/repair system. In: Immune Mechanisms in Cutaneous Disease. Marcel Dekker, New York (1989):425–455.
   Google Scholar
• GOTTLIEB A, LIFSHITZ B, FU S et al.: Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active pso-riatic plaques. J. Exp. Med. (1986) 164:1013–1028.
   PubMed Web of Science ®Google Scholar
• TERUI T, AIBA S, KATO T, TANAKA T, TAGAMI H: HLA-DR antigen expression on keratinocytes in highly inflamed parts of psoriatic lesions. Br. J. Dermatol. (1987) 116:87–93.
   PubMed Web of Science ®Google Scholar
• SAIAG P, COULOMB B, LEBRETON C, BELL E, DUBERTRET L: Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science (1985) 230:669–672.
   PubMed Web of Science ®Google Scholar
• KONSTANTINOVA NV, DUONG D-MT, REMENYIK E et al.: IL-8 is induced in skin equivalents and is highest in those derived from psoriatic keratinocytes. J. Invest. Dermatol. (1996) 107:613–621.
   Google Scholar
• BREATHNACH SM: The skin immune system and psoria-sis. Clin. Exp. Immunol. (1993) 91:343–345.
   PubMed Web of Science ®Google Scholar
• BAKER BS, FRY L: Immunology of psoriasis. Br. J. Derma-tol. (1992) 126:1–9.
   PubMed Web of Science ®Google Scholar
• KUPPER TS: Cytokines in pathophysiologic responses in skin: recruitment of inflammatory infiltrates to cu-taneous tissues. In: Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis and Therapy. Oppenheimer JS, Rossio JL, Gearing ASH (Eds.), Oxford University Press, Oxford, UK (1993):252–255.
   Google Scholar
• TAYLOR R: Cytokine networks: immunobiology sur-faces. J. NIH Res. (1991) 3:71–74.
   Google Scholar
• ELDER JT, FISHER GJ, ZHANG QY et al. Retinoic acid receptor gene expression in human skin. J. Invest. Dermatol (1991) 96:425–433.
   PubMed Web of Science ®Google Scholar
• KRUST A, KASTNER PH, PETKOVICH M et al.: A third human retinoic acid receptor, hRAR-y. Proc. Natl. Acad. Sci. USA (1989) 86:5310–5314.
   PubMed Web of Science ®Google Scholar
• THACHER SM, KLEIN E, AREFIEG T eta]. The comparative pharmacology of the acetylenic retinoid tazarotene in skin and receptor-based assay. 53rd Annual Meeting of the American Academy of Dermatology (4–9 February 1995). Abstract.
   Google Scholar
• NAGPAL S, PATEL S, ASANO AT et al.: Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J. Invest. Dermatol (1996) 106:269–274.
   Google Scholar
• ASANO AR, NAGPAL S, TOWNSEND B et al.: Retinoid responsive gene expression is associated with clinical response to topical AGN 190168 (Tazarotene) in psoria-sis [Abstract]. J. Invest. Dermatol (1995) 194:694.
   Google Scholar
• ESGLEYES-RIBOT T, CHANDRARATNA RA, LEW-KAYA DA et al.: Response of psoriasis to a new topical retinoid, AGN 190168. J. Am. Acad. Dermatol. (1994) 30:581–590.
   PubMed Web of Science ®Google Scholar
• FRANZ TJ, LEHMAN PA, FRANZ S et al.: Percutaneous absorption of AGN 190168, a new synthetic retinoid, through human skin in viva Clin. Res. (1992) 40:533A.
   Google Scholar
• CHANDRARATNA RA: Tazarotene: first of a new genera-tion of receptor-selective retinoids. Br. J. Dermatol (1996) 135 (Suppl. 49):18–25.
   Google Scholar
• LEW-KAYA DA, SEFTON J, KRUEGER GG eta].: Safety and efficacy of a new retinoid gel in the treatment of psoriasis. J Invest. Dermatol (1992) 98:600.
   Google Scholar
• WEINSTEIN GD, GREEN L, DRAKE LA et al.: New topical retinoid gel for therapy of psoriasis: dose-ranging study of AGN 190168. J. Invest. Dermatol. (1993) 100:544.
   Web of Science ®Google Scholar
• WEINSTEIN G, JEFFES E, DUVIC M et al.: Tazarotene gel for the treatment of plaque psoriasis: a double-blind clinical study [Abstract]. J Invest. Dermatol. (1995) 104:661.
   Web of Science ®Google Scholar
• WEINSTEIN G et al.: Tazarotene gel, a new retinoid, for topical therapy of psoriasis. Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect." Am. Acad. Dermatol. (1997) 37(1). (In Press).
   Google Scholar
• LEBWOHL M: Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of stable plaque psoriasis. J. Am. Acad. Dermatol. (In Press).
   Google Scholar
• MATSUMOTO RM, TANG-LIU D, LEW-KAYA D, SEFTON J: Pharmacokinetics of AGN 190168, a novel retinoid, after topical dosing of a 0.1% or 0.05% gel in healthy male volunteers. Pharm. Res. (1994) 11 (Suppl.) :368.
   Google Scholar
• Product Information for Tegisori.
   Google Scholar
• GRONHOJ LARSEN F, VAHLQUIEST C, ANDERSON E et al.: Oral acitretin in psoriasis: drug and vitamin A concen-trations in plasma, skin and adipose tissue. Acta Derma-tol Venetic)]. (Stockholm) (1992) 72:84–88.
   PubMed Web of Science ®Google Scholar